Cancer Immunotherapy

Author:   David B. Teplow (Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA)
Publisher:   Elsevier Science Publishing Co Inc
ISBN:  

9780443235344


Pages:   282
Publication Date:   01 November 2024
Format:   Hardback
Availability:   Not yet available   Availability explained
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Our Price $451.44 Quantity:  
Pre-Order

Share |

Cancer Immunotherapy


Add your own review!

Overview

Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma. Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.

Full Product Details

Author:   David B. Teplow (Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
ISBN:  

9780443235344


ISBN 10:   0443235341
Pages:   282
Publication Date:   01 November 2024
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Forthcoming
Availability:   Not yet available   Availability explained
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Table of Contents

1. The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy Matt Giacalone 2. TBA Tiziana Vavalà 3. Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy Rio Sugimura and Logan Tang 4. Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance? Moein Ala, Fatemeh Afra, Seyed Parsa Eftekhar and Amir Salehi Farid 5. Rational Design of adjuvants boosts cancer vaccines Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki and Nobutaka Hanagata 6. Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma Khushwant S. Yadav 7. MAGNETIC NANOPARTICLES: AN EMERGING NANOMEDICINE FOR CANCER IMMUNOTHERAPY Phoomipat Jungcharoen, Jutatip Panaampon, Thanit Imemkamon and Charupong Saengboonmee 8. TBA Mi Liu 9. TBA Sarbajit Mukherjee 10. TBA Gerardo Cazzato III 11. Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment Eric Jou

Reviews

Author Information

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid ß-protein (Alzheimer's disease) and a-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

lgn

al

Shopping Cart
Your cart is empty
Shopping cart
Mailing List